ELCC 2017 | Targeted therapies for advanced NSCLC

Martin Reck, MD, PhD from the Lungen Clinic Grosshansdorf, Grosshansdorf, Germany discusses how targeted therapies for patients with advanced non-small cell lung cancer (NSCLC) have been a success. The concept of exploiting oncogenic alterations, such as the EGFR mutation or ALK translocation, has improved treatment outcomes. This interview was recorded at the annual meeting of European Lung Cancer Conference (ELCC) in Geneva, Switzerland.